baxter-international
(3)
Stacey Eisen and the Quiet Architecture of Corporate Trust
For more than two decades, Stacey Eisen has worked where reputation, responsibility and the words a company chooses all meet. At Baxter, her remit now stretches from global communications and corporate marketing to the foundation that turns corporate purpose into community programs.
Serge Messerlian
Serge Messerlian is the Chairman and CEO of Creyon Bio, a San Diego biotech using AI to design oligonucleotide medicines. A life-science operator with more than 25 years across oncology, hematology, immunology and rare disease, he has led Teon Therapeutics as CEO, run Janssen Oncology as President at Johnson & Johnson, and held senior roles at Actelion, Baxalta and Baxter International. He joined Creyon first as an investor and board member through DCVC Bio, then stepped in as Executive Chairman and Acting CEO in fall 2024 and took the full CEO title in April 2025 as the company prepares to enter the clinic in 2026.
Andy Kidd
Andy Kidd is the chief executive officer of Tentarix Biotherapeutics, a San Diego company building conditionally active multispecific biologics for oncology and autoimmune disease through its Tentacles platform. A physician turned operator, he carries an unusual pairing of credentials - an M.D. from Oxford and a CFA - and spent over two decades crossing from the consulting room into the boardroom, from Boston Consulting Group to Baxter International to the helm of Nasdaq-listed Aptinyx, which he took public. He stepped into the Tentarix CEO seat in April 2024 to scale a science-heavy startup backed by partnerships with Gilead and AbbVie.